From the Research
Hypermobile Ehlers-Danlos Syndrome (hEDS) can affect fibrin and overall clotting function in some patients, leading to bleeding tendencies and potentially increased risk of thrombosis. While hEDS primarily affects collagen and connective tissue, there is evidence suggesting abnormalities in fibrin structure and function in some individuals with this condition, as discussed in a study published in 2019 1. These patients may experience both bleeding tendencies, such as easy bruising, prolonged bleeding after injury, or heavy menstrual periods, and paradoxically, increased risk of thrombosis in some cases. The fibrin abnormalities appear to create clots with altered structure, sometimes forming looser, more porous clots that break down more easily, contributing to bleeding issues. This occurs because the genetic mutations affecting collagen can also impact related proteins involved in the clotting cascade, as noted in a study from 2021 2. Some key points to consider include:
- The high frequency of bleeding tendencies in patients with hEDS, even in those with normal tests for haemostasis, as reported in a study from 1991 3
- The potential for cardiovascular manifestations, such as mitral valve prolapse and aortic root dilatation, as discussed in a study from 2022 4
- The importance of considering hEDS in patients with joint hypermobility and bleeding or clotting symptoms, as specialized coagulation testing may be warranted to assess fibrin function and determine appropriate management strategies. Overall, while the evidence is not yet fully understood, it is clear that hEDS can have significant effects on fibrin and clotting function, and patients with this condition should be closely monitored for bleeding and clotting symptoms.